Engflag

Esilgan

Quick links to important sections

Esilgan

Esilgan_ID

Method of action: Anxiolytic, Hypnotic, Muscle Relaxant, Psycholeptics, Sedative

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esilgan

Quick Facts

Property Description
Active ingredient Estazolam
Form Oral tablet
Pharmacological class Benzodiazepine / CNS Depressant
Common use Hypnotic (to support sleep)
Origin Synthetic compound (Triazolobenzodiazepine)

Defining Esilgan: Composition and Pharmacological Class

Esilgan is a brand name for the pharmaceutical preparation containing the active ingredient Estazolam, which is a synthetic compound derived from a triazolo ring fused to a benzodiazepine structure. This places it as a triazolobenzodiazepine derivative within the broader Benzodiazepine class of psycholeptic medications, fundamentally categorized as a Central Nervous System (CNS) Depressant. Unlike combination products, Esilgan is a single-ingredient oral tablet, relying on Estazolam alone to produce its effects. This specific triazolobenzodiazepine sub-class, to which Estazolam belongs, is characterized by a shorter duration of action compared to older benzodiazepines.

Estazolam is considered a controlled substance due to its properties, differentiating it from over-the-counter sleep aids and placing it strictly within the prescription-only (Rx) domain. The medication's classification as a Benzodiazepine establishes its use in contexts where central nervous system modulation is required.

The Core Purpose of This Hypnotic Drug

The overall purpose of Estazolam is to serve as a hypnotic agent, achieved by promoting the action of the brain's main calming chemical, gamma-aminobutyric acid (GABA). This enhancement of the brain's natural inhibitory process leads to a reduced level of neural excitability. The general benefit is associated with promoting the onset and maintenance of sleep for adults who experience sleep cycle disruptions.

For instance, this medication is typically utilized in scenarios where an individual needs support to achieve and sustain a state of rest throughout the night. Its classification as a hypnotic ensures its function is confined to supporting sleep, setting it apart from agents used predominantly for anxiety or muscle relaxation.

Regulatory References

  1. Estazolam: MedlinePlus Drug Information

What side effects are possible with Esilgan?

Possible Side Effects and Safety Information

The safety profile of Esilgan (Estazolam) is structured around official classifications that detail the nature and incidence of potential adverse reactions, special risks for vulnerable groups, and high-level use constraints.

Frequency-Classified Adverse Reactions

Adverse reactions are officially grouped by incidence, primarily involving the Nervous System and Psychiatric domains.

Classification Examples of Documented Effects
Common Somnolence (drowsiness), headache, fatigue (asthenia), dizziness, and dry mouth.
Less Common Confusion, depression, abnormal coordination, and memory impairment.
Not Known Paradoxical reactions (e.g., agitation, restlessness) and physical dependence.

Serious Adverse Reactions and Restrictions

The most clinically significant risks, as highlighted in regulatory information, include Respiratory Depression, which is potentially life-threatening, especially when the medicine is used alongside other Central Nervous System (CNS) depressants. Prolonged use is officially associated with the development of Hypnotic Dependence and the risk of severe withdrawal symptoms upon abrupt cessation. The potential for Complex Sleep Behaviors, such as sleep-driving, is also documented.

Population-Specific Safety Notes

Safety constraints are noted for specific groups. Older Adults are officially documented to have an increased sensitivity to the drug's effects, which can result in severe drowsiness, dizziness, and a higher risk of falls. Furthermore, the use of Estazolam may be restricted or contraindicated in individuals with severe hepatic impairment due to reduced clearance.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Esilgan

This section summarizes the official descriptions of overdose and the emergency actions required as stated in government regulatory documents.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Initial manifestations include excessive sleepiness (somnolence), confusion, slurred speech, and loss of coordination; symptoms may progress to a comatose state [Source: DailyMed].
Physiological systems affected (as stated in label) Severe outcomes are primarily seen in the central nervous system and respiratory system, leading to shallow or slowed breathing (respiratory depression) [Source: FDA].
Dose-related or exposure-related factors The risk of profound sedation, coma, and death is substantially increased when Estazolam is taken concomitantly with opioids, alcohol, or other CNS depressants [Source: DailyMed Boxed Warning].
Population-specific overdose notes Elderly patients are at higher risk for severe adverse outcomes due to increased susceptibility to central nervous system effects [Source: FDA].
Emergency-response statements (as written in official documents) Get emergency help right away if symptoms are severe; official guidance directs contacting the Poison Control Helpline [Source: MedlinePlus].
When immediate medical help is required (label-derived phrasing only) Immediate medical attention is required if the victim has shallow or slowed breathing, excessive sleepiness, or cannot be awakened [Source: DailyMed, MedlinePlus].

Overdose Classifications (High-Level)

Domain Official Regulatory Statement
Severity classification (as defined in official documents) Overdose has the potential to lead to serious side effects including coma and death [Source: FDA].
Regulatory basis (EMA / FDA / etc.) The overdose information, particularly concerning co-ingestion risks, is based on FDA prescribing information [Source: DailyMed].
Overdose-context constraints (as defined in official documents) Management is centered on symptomatic and supportive treatment; the antagonist Flumazenil is available but must be used cautiously and not as a substitute for basic airway management [Source: NIH/NCBI].

Resulting Overdose Structure

Official overdose statements:

  • Documented overdose presentations may progress rapidly from confusion and slurred speech to coma and loss of consciousness.
  • The most life-threatening regulatory outcome is respiratory depression, which, particularly with co-ingestion of opioids or alcohol, carries a significant risk of death.
  • It is explicitly mandated to get emergency help right away if signs of slowed breathing or unresponsiveness are observed.
  • Management procedures involve providing symptomatic and supportive treatment, with continuous monitoring of vital signs.

Connection to the overall overdose profile

Regulatory documents define the Estazolam overdose profile by documenting the escalating symptoms of CNS depression and the critical risk of respiratory compromise. This framework establishes clear, non-advisory triggers, such as slowed breathing or unresponsiveness, that immediately necessitate emergency medical attention as officially required by governmental guidance.

Therapeutic Uses of Esilgan

Quick Facts

  • Primary Therapeutic Use: Management of short-term insomnia.
  • Symptom Relief: May help with difficulty falling asleep, frequent nighttime awakenings, and/or waking too early.

What Esilgan Treats: Main Uses and Benefits

Esilgan, which contains the active substance estazolam, is indicated for the short-term management of insomnia. This therapeutic domain is defined by sleep disturbances such as difficulty initiating sleep, waking up repeatedly during the night, and early morning waking. By addressing these symptoms, the medication may help facilitate the ability to fall asleep and maintain sleep for a suitable duration.

The clinical use of this agent is typically reserved for instances where the sleep disturbance has a significant impact on daily function or distress. It may contribute to improving overall sleep quality for a short duration of use, which can potentially lead to better rest. The established indications for the medication emphasize its use as a temporary aid, supporting individuals through acute periods of sleep difficulty.

For a full therapeutic overview and guidance on its approved use, patients and caregivers should consult professional medical resources.

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility profile for Esilgan (Estazolam) is strictly defined by regulatory documents, distinguishing between approved use, contraindications, and restricted populations. The medication is only approved for use in the adult population (18 years and older); its safety and efficacy have not been established in pediatric patients.

Absolute regulatory constraints prohibit use in several populations:

Category Regulatory Status
Pregnancy Contraindicated (Category X)
Hypersensitivity Contraindicated (Estazolam/any benzodiazepine)
Drug-Drug Contraindicated with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole)
Lactation Not Recommended

A patient who previously experienced angioedema following treatment must not be rechallenged with the drug. Special restrictions apply to several populations:

Older adults are a restricted-use group requiring caution due to increased risk of central nervous system (CNS) adverse effects and falls. Caution is also advised for patients with hepatic or renal impairment, those with compromised respiratory function, and individuals with a history of substance abuse or dependence.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estazolam (the active ingredient in Esilgan) is primarily metabolized by the CYP3A4 enzyme system, which forms the basis for its documented pharmacokinetic interactions. The most significant concern involves agents that depress the Central Nervous System (CNS), leading to profound additive effects.

Interacting Product Category Interaction Summary Regulatory Classification
Potent CYP3A4 Inhibitors Significantly increase estazolam plasma concentrations by decreasing clearance. Specific examples include ketoconazole and itraconazole. Contraindicated (Do not use together)
Opioids and Alcohol Cause profound sedation, respiratory depression, coma, and death due to additive CNS depressant effects. Opioids include agonists and partial agonists. Black Box Warning / Avoidance (Use only if alternatives are inadequate; alcohol must be avoided)
Lesser CYP3A4 Inhibitors May decrease estazolam clearance, leading to increased plasma concentrations. Examples include nefazodone, fluvoxamine, cimetidine, diltiazem, and macrolide antibiotics. Use with Caution (Consider estazolam dosage reduction)
CYP3A4 Inducers May increase estazolam clearance, resulting in decreased plasma concentrations and reduced effect. Rifampin is an example. Use with Caution

Additional official notes state that estazolam should not be taken with or immediately after a meal as food can alter blood levels and effects. Grapefruit and grapefruit juice may also increase estazolam levels and potential side effects.

Mechanism of Action

How Esilgan Works: Mechanism of Action

Esilgan acts as a Positive Allosteric Modulator (PAM) by engaging the GABA-A receptor complex, the principal inhibitory signaling system in the Central Nervous System (CNS). The drug binds to a specific site on the receptor, which enhances the receptor's sensitivity to the neurotransmitter GABA. This molecular interaction causes a subsequent increase in the frequency of the chloride ion ( Cl^-) channel opening.

The resulting influx of negative chloride ions into the neuron causes hyperpolarization of the cell membrane, effectively limiting its ability to fire an action potential. This comprehensive, systemic inhibition modulates pathways including the ascending arousal and limbic systems, which regulate processes such as wakefulness and emotional tone. The consequence of this CNS depression includes core physiological changes such as sedation, reduced excitability in emotional centers, and skeletal muscle relaxation.

This mechanism is subject to saturable receptor capacity, meaning its effect is constrained by the concentration of endogenous GABA. Furthermore, prolonged modulation can engage physiological feedback loops that may lead to molecular adaptations, governing the duration and degree of the drug's action.

Dosage and Administration Information

Instruction Map: How to use Esilgan — Administration Guidelines

Administration Scope

Entity Instruction
Route of administration: Oral (tablet form).
Dosing schedule: Adults: The initial dose is 1 mg at bedtime. The usual dose range is 1 mg to 2 mg.
Timing in relation to meals (if applicable): Must not be taken with or immediately following a meal.
Preparation requirements (if applicable): None specified beyond oral intake of the intact tablet.
Age-group administration rules: Older adults: An initial dose of 0.5 mg should be considered for small or debilitated patients, while others may start with 1 mg.
Missed-dose rules: A missed dose should be skipped if it is almost time for the next dose; take only when unable to sleep.
Special procedural conditions: Must be taken only when the user is able to commit to a full night’s sleep (7 to 8 hours) before resuming activity.

Instruction Classifications (High-level)

Classification Detail
Administration method type: Oral
Frequency pattern: Once daily (at bedtime)
Basis of guidelines: Standard clinical and pharmaceutical monographs.
Use-context constraints: The use is conditioned on time of day, food intake, and sleep duration commitment.

Resulting Procedural Structure

Step sequence:

  • Take the tablet once daily at the required time (immediately before going to bed or when experiencing sleep difficulty).
  • Ensure the tablet is taken on an empty stomach (or not immediately after a meal).
  • Follow the prescribed duration of use, which is typically short-term (usually 7 to 10 days).
  • When discontinuing the medication, a gradual reduction (tapering) process is specified to minimize adverse effects.

Connection to the overall use protocol

The instructions establish Estazolam as a time-bound treatment that must be taken orally and once per day immediately before sleep. This regimen mandates specific conditions—such as avoiding food during administration and committing to a 7 to 8-hour sleep window—to ensure proper dosage delivery and alignment with its short-term use. These procedures serve to standardize the proper use of the medication.

Recent Clinical Evidence

Esilgan: Recent Clinical Evidence

Mechanism and Primary Study Focus

Initial research investigated the potential biological activity of the compound. Research explored the relationship between the compound and changes in symptoms associated with sleep disorders over time.

Esilgan (Estazolam) is classified as a benzodiazepine. Its clinical development involved studies focusing on its effects related to sleep latency (the time it takes to fall asleep) and sleep maintenance (the ability to stay asleep).

Randomized controlled trials (RCTs) evaluated the effect of the treatment in participants diagnosed with chronic insomnia. The trials recorded mean changes in objective measures of sleep quality.

Findings from Summarized Data

A meta-analysis summarized findings regarding changes in total sleep time and wakefulness after sleep onset in the participant group versus the placebo group. The study authors noted variability in outcomes across the included trials, a common finding in sleep research.

Subgroup analysis explored the compound’s effect in different demographics, including younger and older adults. Findings regarding the duration of effect were not uniform across all demographics examined, suggesting individual responses may vary.

Important Note on Interpretation

Information about clinical studies describes the data evaluated, reporting on measures such as mean changes in sleep parameters. This information is not a substitute for professional medical consultation, which is necessary to discuss the compound’s suitability for individual health needs.

Key Studies & References

  1. Label: ESTAZOLAM tablet (Official Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Esilgan (FAQ)

Q: What should I do if I overdose on Esilgan?

A: Official regulatory information provides a strong warning that misuse of Estazolam can lead to a serious overdose, which includes the risk of coma and death. Signs of a severe overdose can involve dangerously shallow or slowed breathing, or a stoppage of breathing. If an overdose is suspected, emergency medical attention should be contacted immediately.

Q: What is the typical recommended duration for Estazolam use?

A: Estazolam is officially indicated for the short-term treatment of insomnia, typically for a duration of 7 to 10 days. Official prescribing information indicates that the potential for developing physical dependence and withdrawal symptoms may increase when the treatment duration is extended.

Q: Does Esilgan cause weight gain?

A: Clinical data reported in official regulatory documents have occasionally listed both weight gain and weight loss among the adverse effects. These effects are generally noted as less common or rare occurrences during treatment.

Q: Is there a generic version of Esilgan?

A: Estazolam, which is the active ingredient in the brand-name medication Esilgan, is generally available as a generic medication in various markets.

Q: Are there warnings about taking Esilgan with stimulants like coffee?

A: Official drug labels contain primary warnings regarding the combination of this medicine with alcohol and other Central Nervous System (CNS) depressants, citing the potential for dangerously additive effects, such as severe sedation. While there is no specific regulatory warning against coffee or caffeine, Esilgan itself is a CNS depressant intended to help you sleep.

How should Esilgan be stored and disposed of?

Official Storage Conditions for Esilgan (Estazolam)

Requirement Details
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, moisture, and direct light; do not refrigerate or freeze.
Container Store in the original, tightly closed, child-resistant container.
Child Safety Keep out of the sight and reach of children and store securely to prevent misuse or theft.

Official Disposal Instructions

Estazolam is a controlled substance, and its disposal is regulated. The preferred method for discarding unused or expired medication is through an authorized drug take-back program. If a take-back program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance like dirt or used coffee grounds, sealed in a bag or can, and placed in the household trash. The medication must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

flagItaly

flagPhilippines

Equivalent of Esilgan found in:

A-Z Index: